ASTEC — Astec Lifesciences Income Statement
0.000.00%
- IN₹13.92bn
- IN₹19.43bn
- IN₹3.81bn
Annual income statement for Astec Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5,549 | 6,766 | 6,282 | 4,582 | 3,813 |
Cost of Revenue | |||||
Gross Profit | 1,781 | 2,369 | 1,695 | 964 | 844 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 4,690 | 5,569 | 5,850 | 5,002 | 4,912 |
Operating Profit | 859 | 1,197 | 431 | -421 | -1,099 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 891 | 1,211 | 349 | -617 | -1,410 |
Provision for Income Taxes | |||||
Net Income After Taxes | 651 | 899 | 256 | -469 | -1,347 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 650 | 899 | 256 | -469 | -1,348 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 650 | 899 | 256 | -469 | -1,348 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 33.2 | 45.8 | 13.2 | -23.9 | -68.7 |
Dividends per Share |